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Thank you for giving us the opportunity to revise our manuscript entitled:  
Patrones de progresión de la actividad física en pacientes con EPOC 
Patterns of physical activity progression in patients with COPD 
The comments and suggestions of the Reviewers are much appreciated and have helped to 
improve the manuscript. 
As suggested by Reviewer 3 we have specified now the pharmacological treatment for COPD in 
the manuscript and the related tables. 
We have also replied to all other comments of the Reviewers as specified in the ‘Response to 
Reviewers’ and in the revised versions of the marked-up and unmarked manuscript. Please find 
attached also the graphical abstract to our manuscript. 
 
The manuscript is not currently under consideration or accepted elsewhere. All authors have 
approved the revised version of the manuscript.  
 
 
Thank you for your consideration.  
 
Sincerely, on behalf of the authors, 
 
Judith Garcia-Aymerich, MD, PhD 
Associate Research Professor 
Barcelona Institute for Global Health 
88 Doctor Aiguader  
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Manuscript ID: ARBR-D-20-00611 
Title: Patrones de progresión de la actividad física en pacientes con EPOC 
Patterns of physical activity progression in patients with COPD  
We thank the Reviewers for the comments that have helped to improve the manuscript. All 
comments have been addressed below.  
 
ANSWERS TO REVIEWER #1: 
Comments to the Author 
General Comments (R1) 
R1 
The authors present for the first time an evaluation of the 
natural change in physical activity over time in COPD patients, showing that 
it is heterogenous with three distinct groups identified over a 12 month 
follow up period. They further show that while most COPD patients are 
inactive at baseline and those that are clinically worse at baseline are 
more likely to stay in this group with follow up, determining which of the 
three distinct groups a patient will wind up in after 12 months of follow up 
is unpredictable.  The authors do an excellent job reviewing the known 
literature, accessing the strengths and weaknesses of their work, and 
contextualizing it in the field. Excellent job. 
 
We are happy and want to thank the Reviewer for such a positive consideration.  
 
  
Respuesta a los revisores (Response to reviewer) Click here to access/download;Respuesta a los revisores
(Response to reviewer);Response to Reviewers.docx
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ANSWERS TO REVIEWER #2: 
Comments to the Author 
General Comments (R2) 
R2 
El presente estudio es muy bienvenido porque aporta conocimiento basado en 
evidencias firmes sobre la actividad física en pacientes con EPOC. Su 
utilidad es indudable por lo novedoso de los objetivos y el análisis 
planteado. Los resultados apoyan la necesidad de monitorización estrecha de 
la actividad física en estos pacientes porque no es predecible con las 
variables clínicas que solemos manejar, y las implicaciones en la enfermedad 
y su pronóstico, así lo aconsejan. Como bien destacan los autores, el 
estudio también demuestra la importancia de incluir a un grupo control en 
los estudios de intervención en actividad física. 
Quiero felicitar a los autores por el estudio realizado, tanto por los 
objetivos planteados como por la metodología empleada. El texto está muy 
bien escrito, se sigue bien a pesar de la complejidad y la cantidad de datos 
que se aportan. También hay que reconocer que la discusión está muy bien 
planteada, en párrafos separados que facilitan la argumentación. Las 
conclusiones son la adecuadas a los resultados obtenidos. 
Las tablas son muy prolijas en datos y el material suplementario es también 
muy extenso, pero en mi opinión es reflejo del trabajo realizado y lo 
encuentro adecuado. 
 
We thank the Reviewer for her/his positive appraisal. We have addressed the comments as follows. 
 
R2C1 
ABSTRACT: El párrafo …" Usando Activo que reduce como referencia, menor 
distancia en la prueba de la marcha de 6 minutos…que aumenta" creo que no se 
entiende tan bienen español como en inglés. Sugiero este cambio: por cada 10 
m menos y por cada punto mas. 
 
We thank the Reviewer for noticing that this sentence does not read well in Spanish and have 




La distancia en la prueba de la marcha de 6 minutos (6MWD) y la disnea se asociaron 
independientemente con ser Inactivo: RRR [95% CI] 0.94 [0.90-0.98] por cada 10 m de 6MWD 
(p=0.001) y 1.71 [1.12-2.60] por cada punto en la escala mMRC (p=0.012), respectivamente, en 
comparación con el patrón Activo que reduce. 
 
R2C2 
INTRODUCCIÓN: En la frase "Given the heterogeneous nature and progression of 
COPD (19), it can be hypothesized that physical activity progression also 
displays different patterns, not captured by mean values." Mean values no 
está claro a qué se refiere. Es actividad física? Por favor, necesita 
aclaración. 
 
We thank the Reviewer for pointing out that this phrase needed further clarification. We have 
changed the text in the Introduction section of our revised version accordingly: 
 
Given the heterogeneous nature and progression of COPD (19), it can be hypothesized that physical 




METODOLOGÍA: La muestra utilizada es heterogénea: nivel primario, 
hospitalario, etc., pero también en relación a la procedencia geográfica 
(Urban training Cataluña, España y la cohorte proActive, de diversos países 
europeos, no españoles). ¿Creen los autores que los resultados obtenidos 
pueden estar influidos por esta circunstancia, al haber agrupado a todos los 
pacientes en una única muestra? Sobre todo, porque los sistemas 
asistenciales sanitarios son diferentes según los países, por ejemplo. Un 
comentario al respecto en la discusión puede ser pertinente. 
 
We agree with the Reviewer that pooling the Urban Training and the PROactive cohorts brings some 
heterogeneity to the overall study population. This fact is considered by the authors a strength of the 
current analysis. On one hand, including patients from diverse severity settings maximises the 
variability in physical activity levels and changes, and thus allows to identify “more representative” 
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patterns than just using a single recruitment setting/severity group. On the other hand, including 
patients from diverse geographic locations allows to indirectly control for residual confounding (e.g., 
unmeasured potential confounders that would distribute differently by setting). For the statistical 
analysis, we used a mixed effects model that accounts for possible heterogeneity in unmeasured 
characteristics related to study and city area.  
 
As suggested by the Reviewer, we have added corresponding statements to the Methods and 
Discussion sections of our revised version.  
 
Methods, Statistical analysis (in manuscript and supplement) 
To assess determinants of physical activity progression patterns, we first compared subjects’ 
characteristics by physical activity patterns and obtained p-values from mixed logistic regression 
models with random intercepts for study and city area to account for the multi-level structure of the 
data for possible heterogeneity in unmeasured characteristics related to study and city area. 
 
Discussion 
A major strength of our study is the inclusion of patients across a broad spectrum of disease 
severities and physical activity in several European cities. making our results applicable to a large 
COPD population; This makes our results applicable (i.e., more representative) to a larger COPD 
population than a single recruitment setting or severity group. In addition, the inclusion of patients 




También es llamativo el nivel de mMRC medio, de menos de grado 2, lo que 
quiere decir que, a pesar de incluir pacientes con obstrucción grave y muy 
grave, la disnea es leve. ¿Esto puede haber influido en la actitud del 
paciente con EPOC a la hora de sus costumbres en actividad física? 
Igualmente sugiero hacer un comentario al respecto 
 
The Reviewer is right that the overall mMRC score of 1.3±0.9 is low. While we believe that this low 
score is related to the fact that we included patients from primary care, it indeed also means that 
even the patients with severe and very severe airflow limitation experienced relatively moderate 
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dyspnea (see Table A). We fully agree with the Reviewer that this may have positively influenced the 
physical activity levels of our patients. 
 
Table A Dyspnea score (mMRC) by airflow limitation severity for the patients included in the present 
analysis (n=291). 
 
Airflow limitation severity (post-bronchodilator FEV1) n (%) mMRC score (0-4) 
   GOLD 1: Mild (FEV1 ≥ 80% predicted) 39 (13) 0.9±0.8 
   GOLD 2: Moderate (50% ≤ FEV1 < 80% predicted) 147 (51) 1.1±0.8 
   GOLD 3: Severe (30% ≤ FEV1 < 50% predicted) 88 (30) 1.6±1.0 
   GOLD 4: Very Severe (FEV1 < 30% predicted) 17 (6) 2.4±0.9 
 
As suggested by the Reviewer we have modified the related statement in the Discussion section as 
follows: 
 
The average lack of 12-month change in step count differs from previous studies that showed overall 
a decrease in physical activity (8,10,11,13). A potential explanation is that most of these studies 
recruited patients from outpatient or pulmonary clinics, which may have slightly more advanced 
disease and reduced variability in physical activity and COPD characteristics as compared to our 
sample including also primary care. Supporting this, the group of patients who started with a lower 
physical activity (59%) was similar in their baseline characteristics to previous studies and also had a 
comparable mean decrease of around 500 steps/day (10,11). Notably, the low overall dyspnea score 
may have positively influenced the physical activity level of our study population. A second 
explanation could lie in the high proportion of male subjects and regional differences in physical 
activity practice (a cohort of patients included in the Mediterranean region (5) had a baseline 
physical activity comparable to the Urban Training sample). These characteristics of our sample could 
justify the two patterns with relatively high baseline physical activity and an average small physical 





ANSWERS TO REVIEWER #3: 
Comments to the Author 
General Comments (R3) 
R3 
Considero que se trata de un estudio interesante al clasificar 
a los pacientes EPOC en función del grado de actividad física.  
 
We thank the Reviewer for her/his positive evaluation. We have addressed the comment as follows. 
 
R3C1 
Sin embargo considero que estos tres patrones de actividad física pueden estar 
influenciados por la intensidad de la intervención en cada paciente EPOC . 
Creo que se debería especificar en el trabajo el tipo de intervención 
farmacológica y no farmacológica ( Rehabilitación ) en todos los pacientes . 
Por ejemplo el adecuado tratamiento farmacológico o no de su enfermedad 
puede condicionar la actividad física . En conclusión creo que es un sesgo 
que hay que especificar. 
 
The Reviewer is certainly right in pointing out that the pharmacological and non-pharmacological 
treatments for COPD may affect physical activity and that these treatments should be specified.  
 
For the pharmacological treatment, we have therefore added the main classes of anti-obstructive 
therapy in line with the recommmendations of the GOLD report 2020 [1] to the Tables 1 and 2, as 
well as to the supplementary Table S1. The distribution of long-acting beta2-agonists (LABA) or long-
acting anti-muscarinics (LAMA) and of the combination treatment (inhaled corticosteroid with LABA 
and/or LAMA) was similar for all three patterns. Of note, specifically for Active Improvers and 
Decliners the pharmacological treatment was very comparable.  
 
As concerns the non-pharmacological treatment, the percentage of patients in a pulmonary 
rehabilitation program at baseline or during follow-up was low (5% and 6%, respectively, Table 1). 
Due to the small numbers, we unfortunately could not test the role of pulmonary rehabilitation for 
the progression patterns. However, for sensitivity analysis we repeated the clustering after excluding 
patients in pulmonary rehabilitation programs at baseline or follow-up which confirmed the results 




We have addressed the pharmacological treatment now in the Methods and Discussion section as 
well as in the Tables 1, 2 and supplementary Table S1. As results about non-pharmacological 




(iv) clinical: post-bronchodilator FEV1 and FVC, the 6-min walking distance (6MWD) test, the COPD 
Assessment test (CAT), the Clinical COPD Questionnaire (CCQ), the modified Medical Research 
Council dyspnea scale (mMRC), the number of acute COPD exacerbations requiring a hospital 
admission in the previous 12 months and during follow-up, body mass index (BMI) and fat free mass 
index (FFMI) by physical examination and bioelectrical impedance, comorbidities from medical 
records, pharmacological treatment for COPD, pulmonary rehabilitation at baseline and follow-up, 
incident diseases during follow-up, and knowledge of baseline physical activity (ie report on request); 
 
Discussion 
Most tellingly, we did not identify any factors that could predict among Active patients, the evolution 
to Improvers or Decliners. Surprisingly, the presence of severe exacerbations during follow-up did not 
play any role. It could be speculated that our harmonized exacerbation data was not detailed enough 
to distinguish the severity of exacerbations, the length of hospital stay or the time from the last 
exacerbation to physical activity assessment at follow-up. We also considered the role of incident 
comorbidities during follow-up, which could have influenced behavior, but they were not 
significantly different for the three patterns. Pharmacological treatment for COPD was not different 
across progression patterns discarding any potential role for treatment inappropriateness. Moreover, 
we did not find an association between the recruitment season and physical activity progression. This 
is in line with the hypothesis that the recruitment season, although possibly affecting the baseline 
levels of physical activity (12,18,33), would not affect the progression pattern during a follow-up of 
12 months. Finally, we did not find an effect of accumulated rainfall on physical activity progression, 






Table 1 Patient characteristics at baseline and at 12-month follow-up for all patients (n=291) 
and by study group (Urban Training and PROactive study). 
 





n = 291 (100%) 
n = 148a  
(51%) 
n = 143a  
(49%) 
Sociodemographic    
Age (years) 68±8 69±8 67±8 
Sex (men) 237 (81) 130 (88) 107 (75) 
Current smoker  52 (18) 30 (20) 22 (15) 
Pack-years 58±41 60±45 56±37 
Education, high school or higher 168 (58) 49 (33) 119 (83) 
Interpersonal    
Living with a partnerb 216 (74) 124 (84) 92 (65) 
Active workerc 36 (12) 16 (11) 20 (14) 
Grandparentingd 67 (45) 67 (45) - 
Dog walkingd 20 (14) 20 (14) - 
Environmental    
Recruitment season    
   Spring 35 (12) 35 (24) 0 (0) 
   Summer 58 (20) 15 (10) 43 (30) 
   Fall 154 (53) 54 (36) 100 (70) 
   Winter 44 (15) 44 (30) 0 (0) 





Urban vulnerability index (from 0 -lowest to 1 –highest)d,g 0.637±0.175 0.637±0.175 - 
Clinical    
FEV1 (% predicted) 58.6±19.3 58.2±17.6 59.0±21.0 
FEV1/FVC ratio 0.51±0.13 0.55±0.12 0.48±0.13 
Airflow limitation severity (post-bronchodilator FEV1)    
   GOLD 1: Mild (FEV1 ≥ 80% predicted) 39 (13) 15 (10) 24 (17) 
   GOLD 2: Moderate (50% ≤ FEV1 < 80% predicted) 147 (51) 80 (54) 67 (47) 
   GOLD 3: Severe (30% ≤ FEV1 < 50% predicted) 88 (30) 45 (30) 43 (30) 
   GOLD 4: Very Severe (FEV1 < 30% predicted) 17 (6) 8 (6) 9 (6) 
6MWD (meters) 477±103 501±83 452±116 
CAT score (0–40) 12.9±7.6 12.2±7.6 13.6±7.5 
CCQ score (0-6) 1.55±0.98 1.40±0.95 1.70±0.98 
C-PPAC amount score (0-100) 69.0±15.8 74.7±14.9 63.8±14.9 
C-PPAC difficulty score (0-100) 78.4±14.5 82.7±13.4 74.5±14.5 
C-PPAC total score (0-100) 73.7±12.8 78.7±11.5 69.2±12.3 
mMRC score (0-4) 1.3±0.9 1.1±0.8 1.5±1.0 
Any COPD exacerbation with hospital admission in previous 12 months 34 (12) 12 (8) 22 (15) 
BMI (kg/m2) 27.6±4.6 28.3±4.6 26.8±4.6 
FFMI (kg/m2) 19.0±3.0 19.6±3.2 18.4±2.8 
Cardiovascular diseaseh 176 (60) 90 (61) 86 (60) 
Ischemic heart diseaseh 29 (10) 13 (9) 16 (11) 
Diabetes mellitush 51 (18) 38 (26) 13 (9) 
LABA or LAMA, alone 41 (14) 23 (16) 18 (13) 
Inhaled corticosteroid with LABA and/or LAMA 179 (62) 80 (54) 99 (71) 
Pulmonary rehabilitation at baseline 15 (5) 6 (4) 9 (6) 
Knowledge of baseline PA 19 (7) 19 (13) 0 (0) 
Psychological    
Anxiety (HAD-A, 0-21) 5±4 5±4 5±4 
Depression (HAD-D, 0-21) 4±3 3±3 5±3 
Physical activity    
Step count (steps/day) 6720±3667 7783±3847 5619±3121 
Time in moderate-to-vigorous physical activity (≥3 METs; min/day) 99.4±45.3 109.1±45.7 89.4±42.8 
Intensity during walking (m/s2) 1.86±0.31 1.88±0.32 1.84±0.29 
Sedentary time (h/day) 10.53±1.94 10.43±1.48 10.64±2.31 
Wearing time (h/day) 14.73±1.56 14.64±0.54 14.81±2.16 
Follow-up data    
Any COPD exacerbation with hospital admission during follow-up 28 (10) 10 (7) 18 (13) 
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Any incident comorbidity during follow-upd,i 34 (23) 34 (23) - 
Pulmonary rehabilitation during follow-up 16 (6) 6 (4) 10 (7) 
Wearing time at follow-up (h/day) 14.52±1.63 14.60±0.61 14.43±2.24 
 
Notes: Data are presented as n (%), mean±SD or median (interquartile range). 
aSome variables have missing values, as follows. Urban Training: 1 in education, 25 in C-PPAC scores, 1 in any COPD 
exacerbation with hospital admission in previous 12 months, 18 in FFMI, 2 in HAD anxiety and depression, 5 in any COPD 
exacerbation with hospital admission during follow-up, 2 in pulmonary rehabilitation during follow-up; PROactive: 1 in living with 
a partner, 21 in average rainfall, 1 in CAT score, 1 in CCQ score, 6 in C-PPAC scores, 8 in FFMI, 3 in LABA or LAMA, alone, 3 
in inhaled corticosteroid with LABA and/or LAMA, 1 in HAD anxiety and depression, 3 in pulmonary rehabilitation during follow-
up. 
bmarital status: living with a partner vs single, widowed or divorced.  
cworking status: active worker (working full-time or part-time) vs. unemployed, housework or retired. 
donly available for Urban Training.  
eonly available for PROactive. 
faverage rainfall was calculated as the mean of the measurements at baseline, 6 and 12 months.  
gThe urban vulnerability index is a measure of socioeconomic status at the census tract level that combines demographic, 
economic, residential and subjective indicators, and ranges from lowest [0] to highest [1] level of neighborhood vulnerability. 
hICD10 codes: I00 to I99 for cardiovascular diseases; I20 to I25 for ischemic heart disease, E14 for diabetes mellitus.  
iincident comorbidities included ICD10 codes C00 to N99. 
Abbreviations: FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: Global Initiative for Chronic 
Obstructive Lung Disease; 6MWD: 6-min walking distance; CAT: COPD Assessment Test; CCQ: Clinical COPD Questionnaire; 
C-PPAC: Clinical visit—PROactive Physical Activity in COPD (higher numbers indicate a better score); mMRC: modified 
Medical Research Council; BMI: body mass index; FFMI: fat free mass index; LABA: long-acting beta2-agonists; LAMA: long-
acting anti-muscarinics; HAD-A: Hospital Anxiety and Depression scale – Anxiety; HAD-D: Hospital Anxiety and Depression 
scale – Depression; MET: metabolic equivalent of task.  
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Table 2 Patient characteristics by physical activity progression pattern (Inactive, Active 



















 n = 173a  
(59%) 
n = 49a  
(17%) 
n = 69a  
(24%) 
  
Urban Training study 59 (34) 39 (80) 50 (72)   
PROactive study 114 (66) 10 (20) 19 (28)   
Sociodemographic      
Age (years) 68±8 69±9 67±7 0.282 0.079 
Sex (men) 137 (79) 41 (84) 59 (86) 0.931 0.789 
Current smoker 33 (19) 5 (10) 14 (20) 0.152 0.152 
Pack-years 60±38 63±52 49±40 0.187 0.082 
Education, high school or higher 124 (72) 20 (42) 24 (35) 0.006 0.452 
Interpersonal      
Living with a partnerc 115 (66) 42 (88) 59 (86) 0.017 0.714 
Active workerd 18 (10) 6 (12) 12 (17) 0.088 0.454 
Grandparentinge 20 (34) 21 (54) 26 (52) 0.039 0.863 
Environmental      







Urban vulnerability index (from 0 
-lowest to 1 –highest)e,h 
0.646±0.176 0.613±0.200 0.646±0.153 0.312 0.369 
Clinical      
FEV1 (% predicted) 55.9±19.8 62.9±15.8 62.4±19.5 0.001 0.875 
FEV1/FVC ratio 0.48±0.14 0.55±0.11 0.55±0.11 0.004 0.904 
6MWD (meters) 446±105 521±90 524±78 <0.001 0.861 
CAT score (0-40) 14.2±7.7 11.5±7.3 10.5±6.6 0.002 0.435 
CCQ score (0-6) 1.74±0.97 1.23±0.91 1.29±0.93 0.001 0.780 
C-PPAC difficulty score  
(0-100)i 
74.9±14.7 82.6±13.6 84.8±11.6 <0.001 0.380 
mMRC score (0-4) 1.5±1.0 1.0±0.8 0.9±0.7 <0.001 0.329 
Any COPD exacerbation with 
hospital admission in previous 
12 months 
24 (14) 4 (8) 6 (9) 0.517 0.918 
BMI (kg/m2) 27.6±5.0 27.5±3.9 27.5±4.2 0.139 0.999 
FFMI (kg/m2) 18.9±3.0 19.3±2.9 19.0±3.1 0.650 0.591 
Cardiovascular diseasej 109 (63) 28 (57) 39 (57) 0.221 0.930 
Ischemic heart diseasej 18 (10) 5 (10) 6 (9) 0.898 0.807 
Diabetes mellitusj 23 (13) 11 (22) 17 (25) 0.412 0.786 
LABA or LAMA, alone 24 (14) 7 (14) 10 (15) 0.796 0.949 
Inhaled corticosteroid with LABA 
and/or LAMA 
115 (67) 28 (57) 36 (53) 0.311 0.658 
Psychological      
Anxiety (HAD-A, 0-21) 5±4 5±3 5±4 0.755 0.774 
Depression (HAD-D, 0-21) 5±3 3±3 3±3 0.009 0.992 
Follow-up data      
Any COPD exacerbation with 
hospital admission during follow-
up 
19 (11) 4 (8) 5 (7) 0.759 0.846 
Any incident comorbidity during 
follow-upe,k 
10 (17) 10 (26) 14 (28) 0.191 0.804 
 
Notes: Data are presented as n (%), mean±SD or median (interquartile range). 
aSome variables have missing values, as follows. Inactive: 15 in average rainfall, 1 in CAT total, 1 in CCQ score, 14 in C-PPAC 
difficulty score, 17 in FFMI, 2 in LABA or LAMA, alone, 2 in inhaled corticosteroid with LABA and/or LAMA, 1 in HAD anxiety 
and depression, 3 in any COPD exacerbation with hospital admission during follow-up; Active Improvers: 1 in education, 1 in 
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living with a partner, 2 in average rainfall, 5 in C-PPAC difficulty score, 4 in FFMI, 1 in HAD anxiety and depression, 1 in any 
COPD exacerbation with hospital admission during follow-up; Active Decliners: 4 in average rainfall, 12 in C-PPAC difficulty 
score, 1 in any COPD exacerbation with hospital admission in previous 12 months, 5 in FFMI, 1 in LABA or LAMA, alone, 1 in 
inhaled corticosteroid with LABA and/or LAMA, 1 in HAD anxiety and depression, 1 in any COPD exacerbation with hospital 
admission during follow-up.  
bp-value from mixed logistic regression models with random effects for study (UT and PROactive) and city area (Badalona, 
Barcelona-center, Barcelona-shore, Mataró, Viladecans/Gavà, Athens, Edinburgh, Groningen, Leuven, London).  
cmarital status: living with a partner vs single, widowed or divorced.  
dworking status: active worker (working full-time or part-time) vs. unemployed, housework or retired. 
eonly available for Urban Training.  
fonly available for PROactive. 
gaverage rainfall was calculated as the mean of the measurements at baseline, 6 and 12 months.  
hThe urban vulnerability index is a measure of socioeconomic status at the census tract level that combines demographic, 
economic, residential and subjective indicators, and ranges from lowest [0] to highest [1] level of neighborhood vulnerability. 
ionly C-PPAC difficulty is provided as C-PPAC amount and total score include steps/day which were used for the generation of 
the PA patterns and therefore cannot be assessed as predictors.  
jICD10 codes: I00 to I99 for cardiovascular diseases; I20 to I25 for ischemic heart disease, E14 for diabetes mellitus. 
kincident comorbidities included ICD10 codes C00 to N99. 
Abbreviations: FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; 6MWD: 6-min walking distance; CAT: 
COPD Assessment Test; CCQ: Clinical COPD Questionnaire; C-PPAC: Clinical visit—PROactive Physical Activity in COPD 
(higher numbers indicate a better score); mMRC: modified Medical Research Council; BMI: body mass index; FFMI: fat free 
mass index; LABA: long-acting beta2-agonists; LAMA: long-acting anti-muscarinics; HAD-A: Hospital Anxiety and Depression 




Table S1 Patient characteristics at baseline for all patients (Urban Training and PROactive 
study, n=412) and for patients with 12-month follow-up vs lost-to follow-up. 
 
 





 n = 412 
(100%) 
n = 291a 
(71%) 
n = 121a 
(29%) 
 
Sociodemographic     
Age (years) 68±8 68±8 68±8 0.745 
Sex (men) 316 (77) 237 (81) 79 (65) 0.001 
Current smoker (yes) 77 (19) 52 (18) 25 (21) 0.508 
Pack-years 58±41 58±41 60±41 0.684 
Education, high school or higher 236 (57) 168 (58) 68 (56) 0.746 
Interpersonal     
Living with a partnerc 291 (71) 216 (74) 75 (63) 0.016 
Active workerd 47 (11) 36 (12) 11 (9) 0.342 
Grandparentinge 89 (43) 67 (45) 22 (39) 0.389 
Dog walking e 26 (13) 20 (14) 6 (11) 0.566 
Environmental     
Recruitment season     
   Spring 55 (13) 35 (12) 20 (16) 
0.161 
   Summer 82 (20) 58 (20) 24 (20) 
   Fall 218 (53) 154 (53) 64 (53) 
   Winter 57 (14) 44 (15) 13 (11) 
Urban vulnerability index (from 0 -lowest to 1 –highest)e,f 0.642±0.178 0.637±0.175 0.655±0.186 0.514 
Clinical     
FEV1 (% predicted) 57.7±18.9 58.6±19.3 55.6±17.9 0.140 
FEV1/FVC ratio 0.51±0.13 0.51±0.13 0.51±0.13 0.699 
Airflow limitation severity (post-bronchodilator FEV1)     
   GOLD 1: Mild (FEV1 ≥ 80% predicted) 52 (13) 39 (13) 13 (11) 
0.259 
   GOLD 2: Moderate (50% ≤ FEV1 < 80% predicted) 207 (50) 147 (51) 60 (50) 
   GOLD 3: Severe (30% ≤ FEV1 < 50% predicted) 125 (30) 88 (30) 37 (30) 
   GOLD 4: Very Severe ( FEV1 <30% predicted) 28 (7) 17 (6) 11 (9) 
6MWD (meters) 461±109 477±103 421±111 <0.001 
CAT score (0–40) 13.3±7.5 12.9±7.6 14.2±7.3 0.094 
CCQ score (0-6) 1.59±0.98 1.55±0.98 1.69±0.98 0.172 
C-PPAC amount score (0-100) 67.8±16.9 69.0±15.8 64.2±19.5 0.024 
C-PPAC difficulty score (0-100) 77.9±14.9 78.4±14.5 76.3±16.0 0.269 
C-PPAC total score (0-100) 72.8±13.6 73.7±12.8 70.3±15.4 0.044 
mMRC score (0-4) 1.4±1.0 1.3±0.9 1.7±1.1 <0.001 
Any COPD exacerbation with hospital admission in previous 
12 months 
49 (12) 34 (12) 15 (13) 0.781 
BMI (kg/m2) 27.7±5.2 27.6±4.6 28.1±6.3 0.306 
FFMI (kg/m2) 18.8±3.2 19.0±3.0 18.4±3.5 0.086 
Cardiovascular diseaseg 240 (59) 176 (60) 64 (54) 0.212 
Ischemic heart diseaseg 40 (10) 29 (10) 11 (9) 0.823 
Diabetes mellitusg 73 (18) 51 (18) 22 (18) 0.817 
LABA or LAMA, alone 56 (14) 41 (14) 15 (13) 0.686 
Inhaled corticosteroid with LABA and/or LAMA 256 (63) 179 (62) 77 (65) 0.557 
Pulmonary rehabilitation at baseline 25 (6) 15 (5) 10 (8) 0.233 
Knowledge of baseline PA 24 (6) 19 (7) 5 (4) 0.348 
Psychological     
Anxiety (HAD-A, 0-21) 5±4 5±4 6±4 0.117 
Depression (HAD-D, 0-21) 4±3 4±3 4±4 0.210 
Physical activity     
Step count (steps/day) 6415±3678 6720±3667 5682±3613 0.010 
Time in moderate-to-vigorous physical activity (≥3 METs; 
min/day) 
95.8±45.9 99.4±45.3 87.0±46.2 0.013 
Intensity during walking (m/s2) 1.84±0.31 1.86±0.31 1.80±0.30 0.050 
Sedentary time (h/day) 10.53±1.93 10.53±1.94 10.52±1.92 0.961 
 
Notes: Data are presented as n (%), mean±SD.  
aSome variables have missing values, as follows. Follow-up: 1 in education, 1 in living with a partner, 1 in CAT total, 1 in CCQ 
score, 31 in C-PPAC scores, 1 in any COPD exacerbation with hospital admission in previous 12 months, 26 in FFMI, 3 in LABA 
or LAMA, alone, 3 in inhaled corticosteroid with LABA and/or LAMA,  3 in HAD anxiety and depression; Lost-to follow-up: 1 in 
living with a partner, 1 in 6MWD, 33 in C-PPAC scores, 3 in any COPD exacerbation with hospital admission in previous 12 
months, 5 in FFMI, 2 in ICD10 codes: I00 to I99 for Cardiovascular diseases; I20 to I25 for Ischemic heart disease, E14 for 
Diabetes mellitus, 3 in LABA or LAMA, alone, 3 in inhaled corticosteroid with LABA and/or LAMA, 1 in HAD depression. 
bp-value from mixed logistic regression models with random effects for study (Urban Training and PROactive), due to small 
numbers random effects for city area were not applied.  
cmarital status: living with a partner vs single, widowed or divorced.  
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dworking status: active worker (working full-time or part-time) vs. unemployed, housework or retired.  
eonly available for Urban Training.  
fThe urban vulnerability index is a measure of socioeconomic status at the census tract level that combines demographic, 
economic, residential and subjective indicators, and ranges from lowest [0] to highest [1] level of neighborhood vulnerability. 
gICD10 codes: I00 to I99 for cardiovascular diseases; I20 to I25 for ischemic heart disease, E14 for diabetes mellitus. 
Abbreviations: FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: Global Initiative for Chronic 
Obstructive Lung Disease; 6MWD: 6-min walking distance; CAT: COPD Assessment Test; CCQ: Clinical COPD Questionnaire; 
C-PPAC: Clinical visit—PROactive Physical Activity in COPD (higher numbers indicate a better score); mMRC: modified 
Medical Research Council; BMI: body mass index; FFMI: fat free mass index; LABA: long-acting beta2-agonists; LAMA: long-
acting anti-muscarinics; HAD-A: Hospital Anxiety and Depression scale - Anxiety; HAD-D: Hospital Anxiety and Depression 
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Introduction: Although mean physical activity in COPD patients declines by 400 to 500 
steps/day annually, it is unknown whether the natural progression is the same for all 
patients. We aimed to identify distinct physical activity progression patterns using a 
hypothesis-free approach and to assess their determinants.  
Methods: We pooled data from two cohorts (usual care arm of Urban Training 
[NCT01897298] and PROactive initial validation [NCT01388218] studies) measuring 
physical activity at baseline and 12 months (Dynaport MoveMonitor). We identified 
clusters (patterns) of physical activity progression (based on levels and changes of 
steps/day) using k-means, and compared baseline sociodemographic, interpersonal, 
environmental, clinical and psychological characteristics across patterns. 
Results: In 291 COPD patients (mean±SD 68±8 years, 81% male, FEV1 59±19%pred) we 
identified three distinct physical activity progression patterns: Inactive (n=173 [59%], 
baseline: 4621±1757 steps/day, 12-month change (Δ): -487±1201 steps/day), Active 
Improvers (n=49 [17%], baseline: 7727±3275 steps/day, Δ: +3378±2203 steps/day) and 
Active Decliners (n=69 [24%], baseline: 11267±3009 steps/day, Δ: -2217±2085 
steps/day). After adjustment in a mixed multinomial logistic regression model using 
Active Decliners as reference pattern, a lower 6-min walking distance (RRR [95% CI] 
0.94 [0.90-0.98] per 10m, p=0.001) and a higher mMRC dyspnea score (1.71 [1.12-2.60] 
per 1 point, p=0.012) were independently related with being Inactive. No baseline 
variable was independently associated with being an Active Improver. 
Conclusions: The natural progression in physical activity over time in COPD patients is 
heterogeneous. While Inactive patients relate to worse scores for clinical COPD 





































































COPD, physical activity, patterns of progression, cluster analysis, determinants 
 
Abbreviations  
BMI, body mass index; CAT, COPD assessment test; CCQ, clinical COPD 
questionnaire; CI, confidence interval; COPD, chronic obstructive pulmonary disease; C-
PPAC, clinical visit—PROactive physical activity in COPD; FEV1, forced expiratory 
volume in 1 second; FFMI, fat free mass index; FVC, forced vital capacity; GOLD, global 
initiative for chronic obstructive lung disease; HAD-A, hospital anxiety and depression 
scale – anxiety; HAD-D, hospital anxiety and depression scale – depression; LABA: 
long-acting beta2-agonists; LAMA: long-acting anti-muscarinics; MET, metabolic 
equivalent of task; mMRC, modified medical research council dyspnea score; 6MWD, 6-
min walking distance; MVPA, moderate to vigorous physical activity; RRR, relative risk 






































































Physical activity is a key prognostic factor in chronic obstructive pulmonary disease 
(COPD), yet poorly understood. COPD patients are less active than healthy controls 
from the early stages of disease onwards (1–3) and this reduced activity has been 
associated with impaired prognosis and accelerated progression of COPD (4,5). For this 
reason, several national and international COPD guidelines recommend encouraging 
patients to maintain a good physical activity level (6,7).  
 
Despite patients’ and health professionals’ efforts, physical activity has been shown to 
exhibit a spontaneous decline of an average of 400 to 500 steps/day per year in COPD 
patients (8–14). Such observed decline has been related, although not consistently, to 
lower lung function levels (10,11), the presence of exacerbations (15–17) or the 
seasonality of testing (eg, decline observed in patients going from summer to winter) 
(12,18). Given the heterogeneous nature and progression of COPD (19), it can be 
hypothesized that physical activity progression also displays different patterns, not 
captured by the mean physical activity values. Two previous studies support this 
hypothesis by showing distinct physical activity trajectories over 9 months after a 
pulmonary rehabilitation program (20,21). However, the reported progression in physical 
activity after rehabilitation programs probably does not reflect how physical activity 
evolves in the wider COPD population nor in an observational setting, where patients 
receive a variable combination of pharmacological and non-pharmacological treatments.  
 
We aimed (1) to identify, using a hypothesis-free approach, distinct patterns of natural 
physical activity progression in COPD patients recruited from diverse settings (primary 



































































assess the baseline sociodemographic, interpersonal, environmental, clinical and 
psychological determinants for the identified patterns. Better understanding of the 
natural progression of physical activity, of potential distinct patterns and of their 
determinants could help to individualize strategies to increase (or prevent a decline in) 
physical activity.  
Methods 
Study design and patient population 
This was an observational (no intervention) cohort study of 12-month follow-up including 
patients from: (1) the usual care arm (n=205) from the Urban Training study (22), that 
recruited patients from primary care and tertiary hospitals in five Catalan seaside 
municipalities (Badalona, Barcelona [center and shore areas], Mataró, Viladecans and 
Gavà); and (2) the clinically stable patients (n=207) from the PROactive validation study 
(23), that recruited patients from primary care settings, rehabilitation centers and tertiary 
hospitals in five European cities (Athens/Greece, Edinburgh and London/United 
Kingdom, Groningen/Netherlands, and Leuven/Belgium). Both studies defined COPD 
according to ATS/ERS (post-bronchodilator forced expiratory volume in 1 second (FEV1) 
to forced vital capacity (FVC) ratio <0.70) (24). Patients were included in the present 
analyses if they had a valid physical activity measure (see below) at baseline and 12-
month follow-up. 
 
Both studies were approved by all local institutional review boards and written informed 




































































Physical activity measurements 
Physical activity was objectively measured using the Dynaport MoveMonitor (McRoberts 
BV, The Hague, The Netherlands) (25) for one week at baseline and follow-up. In Urban 
Training, patients wore the monitor for 24 hours and data during waking hours (from 
07:00 h to 22:00 h) were retrieved. In PROactive, patients wore the device during waking 
hours. A valid physical activity measurement was defined as a minimum of three days 
with at least 8 hours of wearing time within waking hours for both studies (26); details 
have been previously published (22,23). A physical activity report was provided to 
patients if requested. 
 
We used step count as the primary outcome to define physical activity progression 
patterns, and time spent in physical activity of moderate to vigorous intensity (MVPA, ≥3 
METs [metabolic equivalents of tasks] min/day), movement intensity (m/s2) during 
walking, and sedentary time (sum of lying and sitting time, hours/day) as secondary 
physical activity outcomes to describe patterns. Physical activity experience was 
assessed by the amount, difficulty and total scores of the Clinical visit-PROactive 
Physical Activity in COPD (C-PPAC) tool (23). 
Other measurements 
We used variables available from both studies (ie exactly the same or equivalent 
standardized questions and procedures had been used) or variables that were available 
from one study only but had been related to physical activity or its evolution in the 
literature: (i) sociodemographic: age, sex, smoking history and education; (ii) 
interpersonal: marital status, working status, grandparenting and dog walking; (iii) 
environmental: season of recruitment, average yearly rainfall and urban vulnerability 



































































bronchodilator FEV1 and FVC, the 6-min walking distance (6MWD) test, the COPD 
Assessment test (CAT), the Clinical COPD Questionnaire (CCQ), the modified Medical 
Research Council dyspnea scale (mMRC), the number of acute COPD exacerbations 
requiring a hospital admission in the previous 12 months and during follow-up, body 
mass index (BMI) and fat free mass index (FFMI) by physical examination and 
bioelectrical impedance, comorbidities from medical records, pharmacological treatment 
for COPD, pulmonary rehabilitation at baseline and follow-up, incident diseases during 
follow-up, and knowledge of baseline physical activity (ie report on request); and (v) 
psychological: the Hospital Anxiety (HAD-A) and Depression (HAD-D) scores. Full 
details on study procedures and quality control have been reported previously 
(22,23,27). 
Statistical analysis 
Sample size calculations, missing data strategy and full statistical analyses are provided 
in the supplement. 
 
We identified cluster groups (physical activity patterns) using k-means (28), a 
hypothesis-free method that allowed grouping patients based on the baseline level, the 
final level and the change in daily step count. To characterize the patterns, we described 
physical activity and physical activity experience variables according to the cluster 
groups and compared baseline to follow-up values by paired t-tests.  
 
To assess determinants of physical activity progression patterns, we first compared 
subjects’ characteristics by physical activity patterns and obtained p-values from mixed 
logistic regression models with random intercepts for study and city area to account for 



































































characteristics related to study and city area. Then we built a multivariable multinomial 
regression model using the generalized linear latent and mixed model, with also random 
intercepts for study and city (29). Model building combined step-forward and backward 
algorithms and we tested goodness of fit of the final model.  
 
As sensitivity analyses, we (1) repeated cluster analysis separately for Urban Training 
and PROactive; (2) tested the association between the change in daily step count and 
the change in wearing time overall and per pattern; and (3) repeated the clustering after 
excluding patients included in pulmonary rehabilitation programs at baseline and/or 
during follow-up.  
 
All analyses were conducted using Stata/SE 14.2 (StataCorp, College Station, TX, 
USA). 
Results 
From 412 patients at baseline, 291 (71%) completed the follow-up visit and were 
included in the current analyses (Figure S1). These patients had a higher proportion of 
males, better functional status and were more active at baseline than those lost-to 
follow-up (Table S1). Included patients were 81% male and had a mean age of 68 years, 
FEV1 of 59% predicted, 6MWD of 477 m, mMRC dyspnea score of 1.3, and walked 6720 
steps/day (Table 1). Compliance with the activity monitor during waking hours was 
excellent: at baseline median (range) valid days of 7 (3-7) and mean±SD wearing hours 
of 14.6±0.5 in Urban Training, and 6 (3-7) days and 14.6±0.5 wearing hours in 
PROactive; and at follow-up, 7 (4-7) days and 14.6±0.6 wearing hours in Urban Training, 



































































At the group level, the step count did not change over 12 months. In the hypothesis-free 
approach, we identified three cluster groups (three distinct physical activity patterns) 
(Figure 1, Table S2). A first cluster (n=173 [59%]), labelled Inactive pattern due to the 
low step count, walked at baseline mean±SD 4621±1757 steps/day and decreased their 
physical activity by 487±1201 steps/day over 12 months. A second cluster (n=49 [17%]), 
labelled Active Improvers, walked 7727±3275 steps/day at baseline and increased by 
3378±2203 steps/day. The third cluster (n=69 [24%]), labelled Active Decliners, walked 
11267±3009 steps/day at baseline and decreased by 2217±2085 steps/day. Distribution 
of MVPA and walking intensity by physical activity pattern followed the same sequence 
as steps/day, except for walking intensity in Active Improvers that did not change. 
Sedentary time did not change for Inactive, decreased for Active Improvers and 
increased moderately for Active Decliners. The physical activity experience as 
expressed by C-PPAC scores did not change for the Inactive pattern; the Active 
Improvers increased the C-PPAC scores (ie, increased amount and reduced difficulty); 
the Active Decliners decreased the C-PPAC amount and total scores while the C-PPAC 
difficulty score did not change (Figure 2, Table S2).  
 
Patients in the Inactive physical activity pattern had a higher degree of education, a 
smaller proportion was living with a partner or grandparenting, and they presented with a 
worse general health status, lower lung function, poorer exercise capacity, worse quality 
of life and higher dyspnea and depression scores than those in the Active Improvers or 
Decliners patterns (Table 2). Active Improvers and Decliners were very similar in their 
baseline characteristics, except for their daily step count.  
 
In the multivariable multinomial logistic regression model we used Active Decliners as the 



































































determinants of being an Active Improver vs Decliner. A lower exercise capacity and a 
higher mMRC dyspnea score were independently related with being Inactive whereas no 
variable was identified as independently associated with being an Active Improver (Table 
3). The final model showed good fit. Sensitivity analyses confirmed the results (Tables S3, 
S4 and S5). 
Discussion 
This study identified, for the first time to our knowledge, the natural progression of 
physical activity in COPD patients. We used a hypothesis-free approach that allowed the 
identification of patterns without a priori assumptions about the physical activity changes 
over time. We found that (1) the natural change in physical activity over time was indeed 
heterogeneous; (2) the majority of patients (59%) was inactive at baseline and 
decreased their physical activity level subsequently; (3) among active individuals some 
increased and some decreased their physical activity level; and (4) although clinical 
COPD characteristics were related to the physical activity level at baseline they could 
not predict subsequent physical activity changes. 
A first important finding is that physical activity progression in COPD is heterogeneous. 
In our 12-month study, mean changes in the full group were virtually zero; however 
when using hypothesis-free clustering methods, we identified one Inactive pattern which 
decreased and two Active patterns which increased or decreased physical activity. This 
observation is in line with previous reports of heterogeneous physical activity 
progression in patients with rheumatoid arthritis (30). The average lack of 12-month 
change in step count differs from previous studies that showed overall a decrease in 
physical activity (8,10,11,13). A potential explanation is that most of these studies 



































































advanced disease and reduced variability in physical activity and COPD characteristics 
as compared to our sample including also primary care. Supporting this, the group of 
patients who started with a lower physical activity (59%) was similar in their baseline 
characteristics to previous studies and also had a comparable mean decrease of around 
500 steps/day (10,11). Notably, the low overall dyspnea score may have positively 
influenced the physical activity level of our study population. A second explanation could 
lie in the high proportion of male subjects and regional differences in physical activity 
practice (a cohort of patients included in the Mediterranean region (5) had a baseline 
physical activity comparable to the Urban Training sample). These characteristics of our 
sample could justify the two patterns with relatively high baseline physical activity and an 
average small physical activity change.  
 
The second important finding is that there seems to exist a group of COPD patients (our 
Active Improvers) that spontaneously increase their physical activity over time. Of note, 
such observed increase of >3000 steps/day is remarkably high given that the minimal 
important difference has been proposed between 600 and 1100 steps/day (31). There 
are several possibilities that would explain this observed increase. First, some patients 
could have been inactive at baseline by chance; however, we tested this option against 
study records by screening for atypical events and it did not hold true. Second, 
regression to the mean could account for part of the increase, but in our data regression 
to the mean was estimated to account for maximal 25% of the effect. Third, changes in 
daily steps could be due to changes in wearing time, but this was not the case in our 
study (Table S4). Fourth, patients could have increased their physical activity after 
participation in rehabilitation programs, but this was dismissed in our analysis (Table 
S5). Finally, we considered that some patients in the usual care arm of Urban Training 



































































study. However, the proportion of patients from Urban Training was similar between 
Active Improvers and Active Decliners. Thus, we suggest that some patients do actually 
increase their physical activity.  
 
The evolution of other physical activity variables provided complementary information. 
Time in MVPA and sedentary time (opposite direction) paralleled the progression of step 
count in all three patterns, supporting previous research that suggested that in COPD 
patients, physical activity and sedentary time provide information about the same 
concept (5). We also investigated the progression of physical activity from the 
perspective of patients. As expected, C-PPAC amount and total scores followed a trend 
similar to the objectively measured physical activity, as they include steps/day in their 
calculation. However, C-PPAC difficulty score remained unchanged in Inactive and 
Active Decliners and increased (ie, less difficulty) in Active Improvers, suggesting that 
the observed increase in amount could be related to experiencing fewer difficulties (less 
dyspnea for instance (32)) while being active. 
 
Our third main finding is the impossibility to predict the physical activity progression 
patterns, despite having included sociodemographic, interpersonal, environmental and 
psychological characteristics in addition to the typical clinical COPD variables. We found 
a large set of COPD-related, functional characteristics associated with the Inactive 
pattern, in accordance with previous, mainly cross-sectional, literature about the 
determinants of physical activity levels in COPD (2,4). Also higher education levels, 
lower social support (living alone, not taking care of grandchildren) and higher 
depression scores related to being in the Inactive pattern, although none of these factors 




































































Most tellingly, we did not identify any factors that could predict among Active patients, 
the evolution to Improvers or Decliners. Surprisingly, the presence of severe 
exacerbations during follow-up did not play any role. It could be speculated that our 
harmonized exacerbation data was not detailed enough to distinguish the severity of 
exacerbations, the length of hospital stay or the time from the last exacerbation to 
physical activity assessment at follow-up. We also considered the role of incident 
comorbidities during follow-up, which could have influenced behavior, but they were not 
significantly different for the three patterns. Pharmacological treatment for COPD was 
not different across progression patterns discarding any potential role for treatment 
inappropriateness. Moreover, we did not find an association between the recruitment 
season and physical activity progression. This is in line with the hypothesis that the 
recruitment season, although possibly affecting the baseline levels of physical activity 
(12,18,33), would not affect the progression pattern during a follow-up of 12 months. 
Finally, we did not find an effect of accumulated rainfall on physical activity progression, 
as recently described cross-sectionally in the same PROactive population (14).  
 
Our study has several implications. It adds to the current knowledge that contrary to the 
general belief not all patients decline but some patients considerably improve their 
physical activity, which should be confirmed in future research and shows the 
importance of including a usual care group in intervention studies. The limitation of 
traditional clinical COPD characteristics to predict physical activity progression suggests 
that further research should broaden the view and give more attention to interpersonal 
and environmental factors potentially related to the individual’s motivation. As the 
optimal timing and use of physical activity interventions to improve physical activity  
(especially in the long term) is still unclear (34), understanding the different COPD 



































































physical activity promotion to reflect different physical activity practices and different 
treatment needs (35). Finally, our results highlight the limitation of using mean 
population values in phenomena that are heterogeneous in nature.  
 
A major strength of our study is the inclusion of patients across a broad spectrum of 
disease severities and physical activity in several European cities. making our results 
applicable to a large COPD population; This makes our results applicable (i.e., more 
representative) to a larger COPD population than a single recruitment setting or severity 
group. In addition, the inclusion of patients from diverse geographic locations allowed us 
to indirectly control for residual confounding. Moreover, we included some variables 
beyond the conventional clinical COPD characteristics (36). The use of the hypothesis-
free clustering approach allowed us to identify patterns of physical activity progression 
based on the distribution of the data without prior assumptions. 
 
However, we acknowledge some shortcomings. We had a small sample size for some of 
the hypothesized determinants of physical activity progression patterns, such as dog 
walking, current pulmonary rehabilitation and knowledge of baseline physical activity, 
which precluded our ability to test their role. Similarly, we did not collect information on 
some physical activity barriers (eg costs or transportation difficulties), which precluded 
testing their role on physical activity progression. The drop-out was 29% which is 
comparable to previous studies (37,38) but the excluded patients had worse functional 
parameters, and we cannot rule out that they would have presented with a fourth, 
potentially declining pattern. The two measurement points available for both studies 
allowed to investigate only linear patterns over time. Having more data points could 
provide more detailed information on the trajectories. In addition, a longer follow-up 



































































this first novel insight into physical activity patterns. Finally, one might argue that pooling 
of the two studies was not appropriate, although our sensitivity analyses showed similar 
cluster results and characteristics and it resulted in a broad spectrum of physical activity 
and COPD severity.  
 
In conclusion, the natural change in physical activity over time in COPD patients is 
heterogeneous and three distinct patterns of physical activity progression have been 
identified: a predominant Inactive pattern, related to worse scores for clinical COPD 
characteristics, and two Active patterns, Improvers and Decliners, which cannot be 
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Table 1 Patient characteristics at baseline and at 12-month follow-up for all patients 
(n=291) and by study group (Urban Training and PROactive study). 
 





 n = 291 
(100%) 
n = 148a  
(51%) 
n = 143a  
(49%) 
Sociodemographic    
Age (years) 68±8 69±8 67±8 
Sex (men) 237 (81) 130 (88) 107 (75) 
Current smoker  52 (18) 30 (20) 22 (15) 
Pack-years 58±41 60±45 56±37 
Education, high school or higher 168 (58) 49 (33) 119 (83) 
Interpersonal    
Living with a partnerb 216 (74) 124 (84) 92 (65) 
Active workerc 36 (12) 16 (11) 20 (14) 
Grandparentingd 67 (45) 67 (45) - 
Dog walkingd 20 (14) 20 (14) - 
Environmental    
Recruitment season    
   Spring 35 (12) 35 (24) 0 (0) 
   Summer 58 (20) 15 (10) 43 (30) 
   Fall 154 (53) 54 (36) 100 (70) 
   Winter 44 (15) 44 (30) 0 (0) 





Urban vulnerability index (from 0 -lowest to 1 –highest)d,g 0.637±0.175 0.637±0.175 - 
Clinical    
FEV1 (% predicted) 58.6±19.3 58.2±17.6 59.0±21.0 
FEV1/FVC ratio 0.51±0.13 0.55±0.12 0.48±0.13 
Airflow limitation severity (post-bronchodilator FEV1)    
   GOLD 1: Mild (FEV1 ≥ 80% predicted) 39 (13) 15 (10) 24 (17) 
   GOLD 2: Moderate (50% ≤ FEV1 < 80% predicted) 147 (51) 80 (54) 67 (47) 
   GOLD 3: Severe (30% ≤ FEV1 < 50% predicted) 88 (30) 45 (30) 43 (30) 
   GOLD 4: Very Severe (FEV1 < 30% predicted) 17 (6) 8 (6) 9 (6) 
6MWD (meters) 477±103 501±83 452±116 
CAT score (0–40) 12.9±7.6 12.2±7.6 13.6±7.5 
CCQ score (0-6) 1.55±0.98 1.40±0.95 1.70±0.98 
C-PPAC amount score (0-100) 69.0±15.8 74.7±14.9 63.8±14.9 
C-PPAC difficulty score (0-100) 78.4±14.5 82.7±13.4 74.5±14.5 
C-PPAC total score (0-100) 73.7±12.8 78.7±11.5 69.2±12.3 
mMRC score (0-4) 1.3±0.9 1.1±0.8 1.5±1.0 
Any COPD exacerbation with hospital admission in previous 12 
months 
34 (12) 12 (8) 22 (15) 
BMI (kg/m2) 27.6±4.6 28.3±4.6 26.8±4.6 
FFMI (kg/m2) 19.0±3.0 19.6±3.2 18.4±2.8 
Cardiovascular diseaseh 176 (60) 90 (61) 86 (60) 
Ischemic heart diseaseh 29 (10) 13 (9) 16 (11) 
Diabetes mellitush 51 (18) 38 (26) 13 (9) 
LABA or LAMA, alone 41 (14) 23 (16) 18 (13) 
Inhaled corticosteroid with LABA and/or LAMA 179 (62) 80 (54) 99 (71) 
Pulmonary rehabilitation at baseline 15 (5) 6 (4) 9 (6) 
Knowledge of baseline PA 19 (7) 19 (13) 0 (0) 
Psychological    
Anxiety (HAD-A, 0-21) 5±4 5±4 5±4 
Depression (HAD-D, 0-21) 4±3 3±3 5±3 
Physical activity    



































































Time in moderate-to-vigorous physical activity (≥3 METs; min/day) 99.4±45.3 109.1±45.7 89.4±42.8 
Intensity during walking (m/s2) 1.86±0.31 1.88±0.32 1.84±0.29 
Sedentary time (h/day) 10.53±1.94 10.43±1.48 10.64±2.31 
Wearing time (h/day) 14.73±1.56 14.64±0.54 14.81±2.16 
Follow-up data    
Any COPD exacerbation with hospital admission during follow-up 28 (10) 10 (7) 18 (13) 
Any incident comorbidity during follow-upd,i 34 (23) 34 (23) - 
Pulmonary rehabilitation during follow-up 16 (6) 6 (4) 10 (7) 
Wearing time at follow-up (h/day) 14.52±1.63 14.60±0.61 14.43±2.24 
 
Notes: Data are presented as n (%), mean±SD or median (interquartile range). 
aSome variables have missing values, as follows. Urban Training: 1 in education, 25 in C-PPAC scores, 1 in any COPD 
exacerbation with hospital admission in previous 12 months, 18 in FFMI, 2 in HAD anxiety and depression, 5 in any 
COPD exacerbation with hospital admission during follow-up, 2 in pulmonary rehabilitation during follow-up; PROactive: 1 
in living with a partner, 21 in average rainfall, 1 in CAT score, 1 in CCQ score, 6 in C-PPAC scores, 8 in FFMI, 3 in LABA 
or LAMA, alone, 3 in inhaled corticosteroid with LABA and/or LAMA, 1 in HAD anxiety and depression, 3 in pulmonary 
rehabilitation during follow-up. 
bmarital status: living with a partner vs single, widowed or divorced.  
cworking status: active worker (working full-time or part-time) vs. unemployed, housework or retired. 
donly available for Urban Training.  
eonly available for PROactive. 
faverage rainfall was calculated as the mean of the measurements at baseline, 6 and 12 months.  
gThe urban vulnerability index is a measure of socioeconomic status at the census tract level that combines demographic, 
economic, residential and subjective indicators, and ranges from lowest [0] to highest [1] level of neighborhood 
vulnerability. 
hICD10 codes: I00 to I99 for cardiovascular diseases; I20 to I25 for ischemic heart disease, E14 for diabetes mellitus.  
iincident comorbidities included ICD10 codes C00 to N99. 
Abbreviations: FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: Global Initiative for 
Chronic Obstructive Lung Disease; 6MWD: 6-min walking distance; CAT: COPD Assessment Test; CCQ: Clinical COPD 
Questionnaire; C-PPAC: Clinical visit—PROactive Physical Activity in COPD (higher numbers indicate a better score); 
mMRC: modified Medical Research Council; BMI: body mass index; FFMI: fat free mass index; LABA: long-acting beta2-
agonists; LAMA: long-acting anti-muscarinics; HAD-A: Hospital Anxiety and Depression scale – Anxiety; HAD-D: Hospital 



































































Table 2 Patient characteristics by physical activity progression pattern (Inactive, Active 



















 n = 173a  
(59%) 
n = 49a  
(17%) 
n = 69a  
(24%) 
  
Urban Training study 59 (34) 39 (80) 50 (72)   
PROactive study 114 (66) 10 (20) 19 (28)   
Sociodemographic      
Age (years) 68±8 69±9 67±7 0.282 0.079 
Sex (men) 137 (79) 41 (84) 59 (86) 0.931 0.789 
Current smoker 33 (19) 5 (10) 14 (20) 0.152 0.152 
Pack-years 60±38 63±52 49±40 0.187 0.082 
Education, high school or 
higher 
124 (72) 20 (42) 24 (35) 0.006 0.452 
Interpersonal      
Living with a partnerc 115 (66) 42 (88) 59 (86) 0.017 0.714 
Active workerd 18 (10) 6 (12) 12 (17) 0.088 0.454 
Grandparentinge 20 (34) 21 (54) 26 (52) 0.039 0.863 
Environmental      







Urban vulnerability index (from 
0 -lowest to 1 –highest)e,h 
0.646±0.176 0.613±0.200 0.646±0.153 0.312 0.369 
Clinical      
FEV1 (% predicted) 55.9±19.8 62.9±15.8 62.4±19.5 0.001 0.875 
FEV1/FVC ratio 0.48±0.14 0.55±0.11 0.55±0.11 0.004 0.904 
6MWD (meters) 446±105 521±90 524±78 <0.001 0.861 
CAT score (0-40) 14.2±7.7 11.5±7.3 10.5±6.6 0.002 0.435 
CCQ score (0-6) 1.74±0.97 1.23±0.91 1.29±0.93 0.001 0.780 
C-PPAC difficulty score  
(0-100)i 
74.9±14.7 82.6±13.6 84.8±11.6 <0.001 0.380 
mMRC score (0-4) 1.5±1.0 1.0±0.8 0.9±0.7 <0.001 0.329 
Any COPD exacerbation with 
hospital admission in previous 
12 months 
24 (14) 4 (8) 6 (9) 0.517 0.918 
BMI (kg/m2) 27.6±5.0 27.5±3.9 27.5±4.2 0.139 0.999 
FFMI (kg/m2) 18.9±3.0 19.3±2.9 19.0±3.1 0.650 0.591 
Cardiovascular diseasej 109 (63) 28 (57) 39 (57) 0.221 0.930 
Ischemic heart diseasej 18 (10) 5 (10) 6 (9) 0.898 0.807 
Diabetes mellitusj 23 (13) 11 (22) 17 (25) 0.412 0.786 
LABA or LAMA, alone 24 (14) 7 (14) 10 (15) 0.796 0.949 
Inhaled corticosteroid with 
LABA and/or LAMA 
115 (67) 28 (57) 36 (53) 0.311 0.658 
Psychological      
Anxiety (HAD-A, 0-21) 5±4 5±3 5±4 0.755 0.774 
Depression (HAD-D, 0-21) 5±3 3±3 3±3 0.009 0.992 
Follow-up data      
Any COPD exacerbation with 
hospital admission during 
follow-up 
19 (11) 4 (8) 5 (7) 0.759 0.846 
Any incident comorbidity during 
follow-upe,k 




































































Notes: Data are presented as n (%), mean±SD or median (interquartile range). 
aSome variables have missing values, as follows. Inactive: 15 in average rainfall, 1 in CAT total, 1 in CCQ score, 14 in C-
PPAC difficulty score, 17 in FFMI, 2 in LABA or LAMA, alone, 2 in inhaled corticosteroid with LABA and/or LAMA, 1 in 
HAD anxiety and depression, 3 in any COPD exacerbation with hospital admission during follow-up; Active Improvers: 1 in 
education, 1 in living with a partner, 2 in average rainfall, 5 in C-PPAC difficulty score, 4 in FFMI, 1 in HAD anxiety and 
depression, 1 in any COPD exacerbation with hospital admission during follow-up; Active Decliners: 4 in average rainfall, 
12 in C-PPAC difficulty score, 1 in any COPD exacerbation with hospital admission in previous 12 months, 5 in FFMI, 1 in 
LABA or LAMA, alone, 1 in inhaled corticosteroid with LABA and/or LAMA, 1 in HAD anxiety and depression, 1 in any 
COPD exacerbation with hospital admission during follow-up.  
bp-value from mixed logistic regression models with random effects for study (UT and PROactive) and city area 
(Badalona, Barcelona-center, Barcelona-shore, Mataró, Viladecans/Gavà, Athens, Edinburgh, Groningen, Leuven, 
London).  
cmarital status: living with a partner vs single, widowed or divorced.  
dworking status: active worker (working full-time or part-time) vs. unemployed, housework or retired. 
eonly available for Urban Training.  
fonly available for PROactive. 
gaverage rainfall was calculated as the mean of the measurements at baseline, 6 and 12 months.  
hThe urban vulnerability index is a measure of socioeconomic status at the census tract level that combines demographic, 
economic, residential and subjective indicators, and ranges from lowest [0] to highest [1] level of neighborhood 
vulnerability. 
ionly C-PPAC difficulty is provided as C-PPAC amount and total score include steps/day which were used for the 
generation of the PA patterns and therefore cannot be assessed as predictors.  
jICD10 codes: I00 to I99 for cardiovascular diseases; I20 to I25 for ischemic heart disease, E14 for diabetes mellitus. 
kincident comorbidities included ICD10 codes C00 to N99. 
Abbreviations: FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; 6MWD: 6-min walking distance; 
CAT: COPD Assessment Test; CCQ: Clinical COPD Questionnaire; C-PPAC: Clinical visit—PROactive Physical Activity 
in COPD (higher numbers indicate a better score); mMRC: modified Medical Research Council; BMI: body mass index; 
FFMI: fat free mass index; LABA: long-acting beta2-agonists; LAMA: long-acting anti-muscarinics; HAD-A: Hospital 




































































Table 3 Adjusted predictive factors for Inactive and Active Improvers vs Active Decliners 
in 291 COPD patients. 
 
 Active Decliners Inactive Active Improvers 
 RRR (95% CI) RRR (95% CI) p-valuea RRR (95% CI) p-valuea 















Notes: ap-value from multinomial regression model with random effects for study (UT and PROactive) and city area 
(Badalona, Barcelona-center, Barcelona-shore, Mataró, Viladecans/Gavà, Athens, Edinburgh, Groningen, Leuven, 
London). 
Abbreviations: RRR: relative risk ratio; CI: confidence interval. 6MWD: 6-min walking distance; mMRC: modified Medical 




































































Figure 1 Physical activity variables at baseline and at 12-month follow-up, overall and by 
PA progression pattern (Inactive, Active Improvers and Active Decliners).  
 
Notes: Data are presented as mean±SE (specific numbers are presented in Table S2). * p-value ≤0.05.  






Figure 2 Physical activity experience variables at baseline and at 12-month follow-up, 
overall and by PA progression pattern (Inactive, Active Improvers and Active Decliners).  
 
Notes: Data are presented as mean±SE (specific numbers are presented in Table S2). * p-value ≤0.05.  
Abbreviations: C-PPAC: Clinical visit—PROactive Physical Activity in COPD (higher numbers indicate a better score).  
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Introduction: Although mean physical activity in COPD patients declines by 400 to 500 
steps/day annually, it is unknown whether the natural progression is the same for all 
patients. We aimed to identify distinct physical activity progression patterns using a 
hypothesis-free approach and to assess their determinants.  
Methods: We pooled data from two cohorts (usual care arm of Urban Training 
[NCT01897298] and PROactive initial validation [NCT01388218] studies) measuring 
physical activity at baseline and 12 months (Dynaport MoveMonitor). We identified 
clusters (patterns) of physical activity progression (based on levels and changes of 
steps/day) using k-means, and compared baseline sociodemographic, interpersonal, 
environmental, clinical and psychological characteristics across patterns. 
Results: In 291 COPD patients (mean±SD 68±8 years, 81% male, FEV1 59±19%pred) we 
identified three distinct physical activity progression patterns: Inactive (n=173 [59%], 
baseline: 4621±1757 steps/day, 12-month change (Δ): -487±1201 steps/day), Active 
Improvers (n=49 [17%], baseline: 7727±3275 steps/day, Δ: +3378±2203 steps/day) and 
Active Decliners (n=69 [24%], baseline: 11267±3009 steps/day, Δ: -2217±2085 
steps/day). After adjustment in a mixed multinomial logistic regression model using 
Active Decliners as reference pattern, a lower 6-min walking distance (RRR [95% CI] 
0.94 [0.90-0.98] per 10m, p=0.001) and a higher mMRC dyspnea score (1.71 [1.12-2.60] 
per 1 point, p=0.012) were independently related with being Inactive. No baseline 
variable was independently associated with being an Active Improver. 
Conclusions: The natural progression in physical activity over time in COPD patients is 
heterogeneous. While Inactive patients relate to worse scores for clinical COPD 





































































COPD, physical activity, patterns of progression, cluster analysis, determinants 
 
Abbreviations  
BMI, body mass index; CAT, COPD assessment test; CCQ, clinical COPD 
questionnaire; CI, confidence interval; COPD, chronic obstructive pulmonary disease; C-
PPAC, clinical visit—PROactive physical activity in COPD; FEV1, forced expiratory 
volume in 1 second; FFMI, fat free mass index; FVC, forced vital capacity; GOLD, global 
initiative for chronic obstructive lung disease; HAD-A, hospital anxiety and depression 
scale – anxiety; HAD-D, hospital anxiety and depression scale – depression; LABA: 
long-acting beta2-agonists; LAMA: long-acting anti-muscarinics; MET, metabolic 
equivalent of task; mMRC, modified medical research council dyspnea score; 6MWD, 6-
min walking distance; MVPA, moderate to vigorous physical activity; RRR, relative risk 






































































Physical activity is a key prognostic factor in chronic obstructive pulmonary disease 
(COPD), yet poorly understood. COPD patients are less active than healthy controls 
from the early stages of disease onwards (1–3) and this reduced activity has been 
associated with impaired prognosis and accelerated progression of COPD (4,5). For this 
reason, several national and international COPD guidelines recommend encouraging 
patients to maintain a good physical activity level (6,7).  
 
Despite patients’ and health professionals’ efforts, physical activity has been shown to 
exhibit a spontaneous decline of an average of 400 to 500 steps/day per year in COPD 
patients (8–14). Such observed decline has been related, although not consistently, to 
lower lung function levels (10,11), the presence of exacerbations (15–17) or the 
seasonality of testing (eg, decline observed in patients going from summer to winter) 
(12,18). Given the heterogeneous nature and progression of COPD (19), it can be 
hypothesized that physical activity progression also displays different patterns, not 
captured by the mean physical activity values. Two previous studies support this 
hypothesis by showing distinct physical activity trajectories over 9 months after a 
pulmonary rehabilitation program (20,21). However, the reported progression in physical 
activity after rehabilitation programs probably does not reflect how physical activity 
evolves in the wider COPD population nor in an observational setting, where patients 
receive a variable combination of pharmacological and non-pharmacological treatments.  
 
We aimed (1) to identify, using a hypothesis-free approach, distinct patterns of natural 
physical activity progression in COPD patients recruited from diverse settings (primary 



































































assess the baseline sociodemographic, interpersonal, environmental, clinical and 
psychological determinants for the identified patterns. Better understanding of the 
natural progression of physical activity, of potential distinct patterns and of their 
determinants could help to individualize strategies to increase (or prevent a decline in) 
physical activity.  
Methods 
Study design and patient population 
This was an observational (no intervention) cohort study of 12-month follow-up including 
patients from: (1) the usual care arm (n=205) from the Urban Training study (22), that 
recruited patients from primary care and tertiary hospitals in five Catalan seaside 
municipalities (Badalona, Barcelona [center and shore areas], Mataró, Viladecans and 
Gavà); and (2) the clinically stable patients (n=207) from the PROactive validation study 
(23), that recruited patients from primary care settings, rehabilitation centers and tertiary 
hospitals in five European cities (Athens/Greece, Edinburgh and London/United 
Kingdom, Groningen/Netherlands, and Leuven/Belgium). Both studies defined COPD 
according to ATS/ERS (post-bronchodilator forced expiratory volume in 1 second (FEV1) 
to forced vital capacity (FVC) ratio <0.70) (24). Patients were included in the present 
analyses if they had a valid physical activity measure (see below) at baseline and 12-
month follow-up. 
 
Both studies were approved by all local institutional review boards and written informed 




































































Physical activity measurements 
Physical activity was objectively measured using the Dynaport MoveMonitor (McRoberts 
BV, The Hague, The Netherlands) (25) for one week at baseline and follow-up. In Urban 
Training, patients wore the monitor for 24 hours and data during waking hours (from 
07:00 h to 22:00 h) were retrieved. In PROactive, patients wore the device during waking 
hours. A valid physical activity measurement was defined as a minimum of three days 
with at least 8 hours of wearing time within waking hours for both studies (26); details 
have been previously published (22,23). A physical activity report was provided to 
patients if requested. 
 
We used step count as the primary outcome to define physical activity progression 
patterns, and time spent in physical activity of moderate to vigorous intensity (MVPA, ≥3 
METs [metabolic equivalents of tasks] min/day), movement intensity (m/s2) during 
walking, and sedentary time (sum of lying and sitting time, hours/day) as secondary 
physical activity outcomes to describe patterns. Physical activity experience was 
assessed by the amount, difficulty and total scores of the Clinical visit-PROactive 
Physical Activity in COPD (C-PPAC) tool (23). 
Other measurements 
We used variables available from both studies (ie exactly the same or equivalent 
standardized questions and procedures had been used) or variables that were available 
from one study only but had been related to physical activity or its evolution in the 
literature: (i) sociodemographic: age, sex, smoking history and education; (ii) 
interpersonal: marital status, working status, grandparenting and dog walking; (iii) 
environmental: season of recruitment, average yearly rainfall and urban vulnerability 



































































bronchodilator FEV1 and FVC, the 6-min walking distance (6MWD) test, the COPD 
Assessment test (CAT), the Clinical COPD Questionnaire (CCQ), the modified Medical 
Research Council dyspnea scale (mMRC), the number of acute COPD exacerbations 
requiring a hospital admission in the previous 12 months and during follow-up, body 
mass index (BMI) and fat free mass index (FFMI) by physical examination and 
bioelectrical impedance, comorbidities from medical records, pharmacological treatment 
for COPD, pulmonary rehabilitation at baseline and follow-up, incident diseases during 
follow-up, and knowledge of baseline physical activity (ie report on request); and (v) 
psychological: the Hospital Anxiety (HAD-A) and Depression (HAD-D) scores. Full 
details on study procedures and quality control have been reported previously 
(22,23,27). 
Statistical analysis 
Sample size calculations, missing data strategy and full statistical analyses are provided 
in the supplement. 
 
We identified cluster groups (physical activity patterns) using k-means (28), a 
hypothesis-free method that allowed grouping patients based on the baseline level, the 
final level and the change in daily step count. To characterize the patterns, we described 
physical activity and physical activity experience variables according to the cluster 
groups and compared baseline to follow-up values by paired t-tests.  
 
To assess determinants of physical activity progression patterns, we first compared 
subjects’ characteristics by physical activity patterns and obtained p-values from mixed 
logistic regression models with random intercepts for study and city area to account for 



































































Then we built a multivariable multinomial regression model using the generalized linear 
latent and mixed model, with also random intercepts for study and city (29). Model 
building combined step-forward and backward algorithms and we tested goodness of fit 
of the final model.  
 
As sensitivity analyses, we (1) repeated cluster analysis separately for Urban Training 
and PROactive; (2) tested the association between the change in daily step count and 
the change in wearing time overall and per pattern; and (3) repeated the clustering after 
excluding patients included in pulmonary rehabilitation programs at baseline and/or 
during follow-up.  
 
All analyses were conducted using Stata/SE 14.2 (StataCorp, College Station, TX, 
USA). 
Results 
From 412 patients at baseline, 291 (71%) completed the follow-up visit and were 
included in the current analyses (Figure S1). These patients had a higher proportion of 
males, better functional status and were more active at baseline than those lost-to 
follow-up (Table S1). Included patients were 81% male and had a mean age of 68 years, 
FEV1 of 59% predicted, 6MWD of 477 m, mMRC dyspnea score of 1.3, and walked 6720 
steps/day (Table 1). Compliance with the activity monitor during waking hours was 
excellent: at baseline median (range) valid days of 7 (3-7) and mean±SD wearing hours 
of 14.6±0.5 in Urban Training, and 6 (3-7) days and 14.6±0.5 wearing hours in 
PROactive; and at follow-up, 7 (4-7) days and 14.6±0.6 wearing hours in Urban Training, 



































































At the group level, the step count did not change over 12 months. In the hypothesis-free 
approach, we identified three cluster groups (three distinct physical activity patterns) 
(Figure 1, Table S2). A first cluster (n=173 [59%]), labelled Inactive pattern due to the 
low step count, walked at baseline mean±SD 4621±1757 steps/day and decreased their 
physical activity by 487±1201 steps/day over 12 months. A second cluster (n=49 [17%]), 
labelled Active Improvers, walked 7727±3275 steps/day at baseline and increased by 
3378±2203 steps/day. The third cluster (n=69 [24%]), labelled Active Decliners, walked 
11267±3009 steps/day at baseline and decreased by 2217±2085 steps/day. Distribution 
of MVPA and walking intensity by physical activity pattern followed the same sequence 
as steps/day, except for walking intensity in Active Improvers that did not change. 
Sedentary time did not change for Inactive, decreased for Active Improvers and 
increased moderately for Active Decliners. The physical activity experience as 
expressed by C-PPAC scores did not change for the Inactive pattern; the Active 
Improvers increased the C-PPAC scores (ie, increased amount and reduced difficulty); 
the Active Decliners decreased the C-PPAC amount and total scores while the C-PPAC 
difficulty score did not change (Figure 2, Table S2).  
 
Patients in the Inactive physical activity pattern had a higher degree of education, a 
smaller proportion was living with a partner or grandparenting, and they presented with a 
worse general health status, lower lung function, poorer exercise capacity, worse quality 
of life and higher dyspnea and depression scores than those in the Active Improvers or 
Decliners patterns (Table 2). Active Improvers and Decliners were very similar in their 
baseline characteristics, except for their daily step count.  
 
In the multivariable multinomial logistic regression model we used Active Decliners as the 



































































determinants of being an Active Improver vs Decliner. A lower exercise capacity and a 
higher mMRC dyspnea score were independently related with being Inactive whereas no 
variable was identified as independently associated with being an Active Improver (Table 
3). The final model showed good fit. Sensitivity analyses confirmed the results (Tables S3, 
S4 and S5). 
Discussion 
This study identified, for the first time to our knowledge, the natural progression of 
physical activity in COPD patients. We used a hypothesis-free approach that allowed the 
identification of patterns without a priori assumptions about the physical activity changes 
over time. We found that (1) the natural change in physical activity over time was indeed 
heterogeneous; (2) the majority of patients (59%) was inactive at baseline and 
decreased their physical activity level subsequently; (3) among active individuals some 
increased and some decreased their physical activity level; and (4) although clinical 
COPD characteristics were related to the physical activity level at baseline they could 
not predict subsequent physical activity changes. 
A first important finding is that physical activity progression in COPD is heterogeneous. 
In our 12-month study, mean changes in the full group were virtually zero; however 
when using hypothesis-free clustering methods, we identified one Inactive pattern which 
decreased and two Active patterns which increased or decreased physical activity. This 
observation is in line with previous reports of heterogeneous physical activity 
progression in patients with rheumatoid arthritis (30). The average lack of 12-month 
change in step count differs from previous studies that showed overall a decrease in 
physical activity (8,10,11,13). A potential explanation is that most of these studies 



































































advanced disease and reduced variability in physical activity and COPD characteristics 
as compared to our sample including also primary care. Supporting this, the group of 
patients who started with a lower physical activity (59%) was similar in their baseline 
characteristics to previous studies and also had a comparable mean decrease of around 
500 steps/day (10,11). Notably, the low overall dyspnea score may have positively 
influenced the physical activity level of our study population. A second explanation could 
lie in the high proportion of male subjects and regional differences in physical activity 
practice (a cohort of patients included in the Mediterranean region (5) had a baseline 
physical activity comparable to the Urban Training sample). These characteristics of our 
sample could justify the two patterns with relatively high baseline physical activity and an 
average small physical activity change.  
 
The second important finding is that there seems to exist a group of COPD patients (our 
Active Improvers) that spontaneously increase their physical activity over time. Of note, 
such observed increase of >3000 steps/day is remarkably high given that the minimal 
important difference has been proposed between 600 and 1100 steps/day (31). There 
are several possibilities that would explain this observed increase. First, some patients 
could have been inactive at baseline by chance; however, we tested this option against 
study records by screening for atypical events and it did not hold true. Second, 
regression to the mean could account for part of the increase, but in our data regression 
to the mean was estimated to account for maximal 25% of the effect. Third, changes in 
daily steps could be due to changes in wearing time, but this was not the case in our 
study (Table S4). Fourth, patients could have increased their physical activity after 
participation in rehabilitation programs, but this was dismissed in our analysis (Table 
S5). Finally, we considered that some patients in the usual care arm of Urban Training 



































































study. However, the proportion of patients from Urban Training was similar between 
Active Improvers and Active Decliners. Thus, we suggest that some patients do actually 
increase their physical activity.  
 
The evolution of other physical activity variables provided complementary information. 
Time in MVPA and sedentary time (opposite direction) paralleled the progression of step 
count in all three patterns, supporting previous research that suggested that in COPD 
patients, physical activity and sedentary time provide information about the same 
concept (5). We also investigated the progression of physical activity from the 
perspective of patients. As expected, C-PPAC amount and total scores followed a trend 
similar to the objectively measured physical activity, as they include steps/day in their 
calculation. However, C-PPAC difficulty score remained unchanged in Inactive and 
Active Decliners and increased (ie, less difficulty) in Active Improvers, suggesting that 
the observed increase in amount could be related to experiencing fewer difficulties (less 
dyspnea for instance (32)) while being active. 
 
Our third main finding is the impossibility to predict the physical activity progression 
patterns, despite having included sociodemographic, interpersonal, environmental and 
psychological characteristics in addition to the typical clinical COPD variables. We found 
a large set of COPD-related, functional characteristics associated with the Inactive 
pattern, in accordance with previous, mainly cross-sectional, literature about the 
determinants of physical activity levels in COPD (2,4). Also higher education levels, 
lower social support (living alone, not taking care of grandchildren) and higher 
depression scores related to being in the Inactive pattern, although none of these factors 




































































Most tellingly, we did not identify any factors that could predict among Active patients, 
the evolution to Improvers or Decliners. Surprisingly, the presence of severe 
exacerbations during follow-up did not play any role. It could be speculated that our 
harmonized exacerbation data was not detailed enough to distinguish the severity of 
exacerbations, the length of hospital stay or the time from the last exacerbation to 
physical activity assessment at follow-up. We also considered the role of incident 
comorbidities during follow-up, which could have influenced behavior, but they were not 
significantly different for the three patterns. Pharmacological treatment for COPD was 
not different across progression patterns discarding any potential role for treatment 
inappropriateness. Moreover, we did not find an association between the recruitment 
season and physical activity progression. This is in line with the hypothesis that the 
recruitment season, although possibly affecting the baseline levels of physical activity 
(12,18,33), would not affect the progression pattern during a follow-up of 12 months. 
Finally, we did not find an effect of accumulated rainfall on physical activity progression, 
as recently described cross-sectionally in the same PROactive population (14).  
 
Our study has several implications. It adds to the current knowledge that contrary to the 
general belief not all patients decline but some patients considerably improve their 
physical activity, which should be confirmed in future research and shows the 
importance of including a usual care group in intervention studies. The limitation of 
traditional clinical COPD characteristics to predict physical activity progression suggests 
that further research should broaden the view and give more attention to interpersonal 
and environmental factors potentially related to the individual’s motivation. As the 
optimal timing and use of physical activity interventions to improve physical activity  
(especially in the long term) is still unclear (34), understanding the different COPD 



































































physical activity promotion to reflect different physical activity practices and different 
treatment needs (35). Finally, our results highlight the limitation of using mean 
population values in phenomena that are heterogeneous in nature.  
 
A major strength of our study is the inclusion of patients across a broad spectrum of 
disease severities and physical activity in several European cities. This makes our 
results applicable (i.e., more representative) to a larger COPD population than a single 
recruitment setting or severity group. In addition, the inclusion of patients from diverse 
geographic locations allowed us to indirectly control for residual confounding. Moreover, 
we included some variables beyond the conventional clinical COPD characteristics (36). 
The use of the hypothesis-free clustering approach allowed us to identify patterns of 
physical activity progression based on the distribution of the data without prior 
assumptions. 
 
However, we acknowledge some shortcomings. We had a small sample size for some of 
the hypothesized determinants of physical activity progression patterns, such as dog 
walking, current pulmonary rehabilitation and knowledge of baseline physical activity, 
which precluded our ability to test their role. Similarly, we did not collect information on 
some physical activity barriers (eg costs or transportation difficulties), which precluded 
testing their role on physical activity progression. The drop-out was 29% which is 
comparable to previous studies (37,38) but the excluded patients had worse functional 
parameters, and we cannot rule out that they would have presented with a fourth, 
potentially declining pattern. The two measurement points available for both studies 
allowed to investigate only linear patterns over time. Having more data points could 
provide more detailed information on the trajectories. In addition, a longer follow-up 



































































this first novel insight into physical activity patterns. Finally, one might argue that pooling 
of the two studies was not appropriate, although our sensitivity analyses showed similar 
cluster results and characteristics and it resulted in a broad spectrum of physical activity 
and COPD severity.  
 
In conclusion, the natural change in physical activity over time in COPD patients is 
heterogeneous and three distinct patterns of physical activity progression have been 
identified: a predominant Inactive pattern, related to worse scores for clinical COPD 
characteristics, and two Active patterns, Improvers and Decliners, which cannot be 
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Table 1 Patient characteristics at baseline and at 12-month follow-up for all patients 
(n=291) and by study group (Urban Training and PROactive study). 
 





 n = 291 
(100%) 
n = 148a  
(51%) 
n = 143a  
(49%) 
Sociodemographic    
Age (years) 68±8 69±8 67±8 
Sex (men) 237 (81) 130 (88) 107 (75) 
Current smoker  52 (18) 30 (20) 22 (15) 
Pack-years 58±41 60±45 56±37 
Education, high school or higher 168 (58) 49 (33) 119 (83) 
Interpersonal    
Living with a partnerb 216 (74) 124 (84) 92 (65) 
Active workerc 36 (12) 16 (11) 20 (14) 
Grandparentingd 67 (45) 67 (45) - 
Dog walkingd 20 (14) 20 (14) - 
Environmental    
Recruitment season    
   Spring 35 (12) 35 (24) 0 (0) 
   Summer 58 (20) 15 (10) 43 (30) 
   Fall 154 (53) 54 (36) 100 (70) 
   Winter 44 (15) 44 (30) 0 (0) 





Urban vulnerability index (from 0 -lowest to 1 –highest)d,g 0.637±0.175 0.637±0.175 - 
Clinical    
FEV1 (% predicted) 58.6±19.3 58.2±17.6 59.0±21.0 
FEV1/FVC ratio 0.51±0.13 0.55±0.12 0.48±0.13 
Airflow limitation severity (post-bronchodilator FEV1)    
   GOLD 1: Mild (FEV1 ≥ 80% predicted) 39 (13) 15 (10) 24 (17) 
   GOLD 2: Moderate (50% ≤ FEV1 < 80% predicted) 147 (51) 80 (54) 67 (47) 
   GOLD 3: Severe (30% ≤ FEV1 < 50% predicted) 88 (30) 45 (30) 43 (30) 
   GOLD 4: Very Severe (FEV1 < 30% predicted) 17 (6) 8 (6) 9 (6) 
6MWD (meters) 477±103 501±83 452±116 
CAT score (0–40) 12.9±7.6 12.2±7.6 13.6±7.5 
CCQ score (0-6) 1.55±0.98 1.40±0.95 1.70±0.98 
C-PPAC amount score (0-100) 69.0±15.8 74.7±14.9 63.8±14.9 
C-PPAC difficulty score (0-100) 78.4±14.5 82.7±13.4 74.5±14.5 
C-PPAC total score (0-100) 73.7±12.8 78.7±11.5 69.2±12.3 
mMRC score (0-4) 1.3±0.9 1.1±0.8 1.5±1.0 
Any COPD exacerbation with hospital admission in previous 12 
months 
34 (12) 12 (8) 22 (15) 
BMI (kg/m2) 27.6±4.6 28.3±4.6 26.8±4.6 
FFMI (kg/m2) 19.0±3.0 19.6±3.2 18.4±2.8 
Cardiovascular diseaseh 176 (60) 90 (61) 86 (60) 
Ischemic heart diseaseh 29 (10) 13 (9) 16 (11) 
Diabetes mellitush 51 (18) 38 (26) 13 (9) 
LABA or LAMA, alone 41 (14) 23 (16) 18 (13) 
Inhaled corticosteroid with LABA and/or LAMA 179 (62) 80 (54) 99 (71) 
Pulmonary rehabilitation at baseline 15 (5) 6 (4) 9 (6) 
Knowledge of baseline PA 19 (7) 19 (13) 0 (0) 
Psychological    
Anxiety (HAD-A, 0-21) 5±4 5±4 5±4 
Depression (HAD-D, 0-21) 4±3 3±3 5±3 
Physical activity    



































































Time in moderate-to-vigorous physical activity (≥3 METs; min/day) 99.4±45.3 109.1±45.7 89.4±42.8 
Intensity during walking (m/s2) 1.86±0.31 1.88±0.32 1.84±0.29 
Sedentary time (h/day) 10.53±1.94 10.43±1.48 10.64±2.31 
Wearing time (h/day) 14.73±1.56 14.64±0.54 14.81±2.16 
Follow-up data    
Any COPD exacerbation with hospital admission during follow-up 28 (10) 10 (7) 18 (13) 
Any incident comorbidity during follow-upd,i 34 (23) 34 (23) - 
Pulmonary rehabilitation during follow-up 16 (6) 6 (4) 10 (7) 
Wearing time at follow-up (h/day) 14.52±1.63 14.60±0.61 14.43±2.24 
 
Notes: Data are presented as n (%), mean±SD or median (interquartile range). 
aSome variables have missing values, as follows. Urban Training: 1 in education, 25 in C-PPAC scores, 1 in any COPD 
exacerbation with hospital admission in previous 12 months, 18 in FFMI, 2 in HAD anxiety and depression, 5 in any 
COPD exacerbation with hospital admission during follow-up, 2 in pulmonary rehabilitation during follow-up; PROactive: 1 
in living with a partner, 21 in average rainfall, 1 in CAT score, 1 in CCQ score, 6 in C-PPAC scores, 8 in FFMI, 3 in LABA 
or LAMA, alone, 3 in inhaled corticosteroid with LABA and/or LAMA, 1 in HAD anxiety and depression, 3 in pulmonary 
rehabilitation during follow-up. 
bmarital status: living with a partner vs single, widowed or divorced.  
cworking status: active worker (working full-time or part-time) vs. unemployed, housework or retired. 
donly available for Urban Training.  
eonly available for PROactive. 
faverage rainfall was calculated as the mean of the measurements at baseline, 6 and 12 months.  
gThe urban vulnerability index is a measure of socioeconomic status at the census tract level that combines demographic, 
economic, residential and subjective indicators, and ranges from lowest [0] to highest [1] level of neighborhood 
vulnerability. 
hICD10 codes: I00 to I99 for cardiovascular diseases; I20 to I25 for ischemic heart disease, E14 for diabetes mellitus.  
iincident comorbidities included ICD10 codes C00 to N99. 
Abbreviations: FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: Global Initiative for 
Chronic Obstructive Lung Disease; 6MWD: 6-min walking distance; CAT: COPD Assessment Test; CCQ: Clinical COPD 
Questionnaire; C-PPAC: Clinical visit—PROactive Physical Activity in COPD (higher numbers indicate a better score); 
mMRC: modified Medical Research Council; BMI: body mass index; FFMI: fat free mass index; LABA: long-acting beta2-
agonists; LAMA: long-acting anti-muscarinics; HAD-A: Hospital Anxiety and Depression scale – Anxiety; HAD-D: Hospital 



































































Table 2 Patient characteristics by physical activity progression pattern (Inactive, Active 



















 n = 173a  
(59%) 
n = 49a  
(17%) 
n = 69a  
(24%) 
  
Urban Training study 59 (34) 39 (80) 50 (72)   
PROactive study 114 (66) 10 (20) 19 (28)   
Sociodemographic      
Age (years) 68±8 69±9 67±7 0.282 0.079 
Sex (men) 137 (79) 41 (84) 59 (86) 0.931 0.789 
Current smoker 33 (19) 5 (10) 14 (20) 0.152 0.152 
Pack-years 60±38 63±52 49±40 0.187 0.082 
Education, high school or 
higher 
124 (72) 20 (42) 24 (35) 0.006 0.452 
Interpersonal      
Living with a partnerc 115 (66) 42 (88) 59 (86) 0.017 0.714 
Active workerd 18 (10) 6 (12) 12 (17) 0.088 0.454 
Grandparentinge 20 (34) 21 (54) 26 (52) 0.039 0.863 
Environmental      







Urban vulnerability index (from 
0 -lowest to 1 –highest)e,h 
0.646±0.176 0.613±0.200 0.646±0.153 0.312 0.369 
Clinical      
FEV1 (% predicted) 55.9±19.8 62.9±15.8 62.4±19.5 0.001 0.875 
FEV1/FVC ratio 0.48±0.14 0.55±0.11 0.55±0.11 0.004 0.904 
6MWD (meters) 446±105 521±90 524±78 <0.001 0.861 
CAT score (0-40) 14.2±7.7 11.5±7.3 10.5±6.6 0.002 0.435 
CCQ score (0-6) 1.74±0.97 1.23±0.91 1.29±0.93 0.001 0.780 
C-PPAC difficulty score  
(0-100)i 
74.9±14.7 82.6±13.6 84.8±11.6 <0.001 0.380 
mMRC score (0-4) 1.5±1.0 1.0±0.8 0.9±0.7 <0.001 0.329 
Any COPD exacerbation with 
hospital admission in previous 
12 months 
24 (14) 4 (8) 6 (9) 0.517 0.918 
BMI (kg/m2) 27.6±5.0 27.5±3.9 27.5±4.2 0.139 0.999 
FFMI (kg/m2) 18.9±3.0 19.3±2.9 19.0±3.1 0.650 0.591 
Cardiovascular diseasej 109 (63) 28 (57) 39 (57) 0.221 0.930 
Ischemic heart diseasej 18 (10) 5 (10) 6 (9) 0.898 0.807 
Diabetes mellitusj 23 (13) 11 (22) 17 (25) 0.412 0.786 
LABA or LAMA, alone 24 (14) 7 (14) 10 (15) 0.796 0.949 
Inhaled corticosteroid with 
LABA and/or LAMA 
115 (67) 28 (57) 36 (53) 0.311 0.658 
Psychological      
Anxiety (HAD-A, 0-21) 5±4 5±3 5±4 0.755 0.774 
Depression (HAD-D, 0-21) 5±3 3±3 3±3 0.009 0.992 
Follow-up data      
Any COPD exacerbation with 
hospital admission during 
follow-up 
19 (11) 4 (8) 5 (7) 0.759 0.846 
Any incident comorbidity during 
follow-upe,k 




































































Notes: Data are presented as n (%), mean±SD or median (interquartile range). 
aSome variables have missing values, as follows. Inactive: 15 in average rainfall, 1 in CAT total, 1 in CCQ score, 14 in C-
PPAC difficulty score, 17 in FFMI, 2 in LABA or LAMA, alone, 2 in inhaled corticosteroid with LABA and/or LAMA, 1 in 
HAD anxiety and depression, 3 in any COPD exacerbation with hospital admission during follow-up; Active Improvers: 1 in 
education, 1 in living with a partner, 2 in average rainfall, 5 in C-PPAC difficulty score, 4 in FFMI, 1 in HAD anxiety and 
depression, 1 in any COPD exacerbation with hospital admission during follow-up; Active Decliners: 4 in average rainfall, 
12 in C-PPAC difficulty score, 1 in any COPD exacerbation with hospital admission in previous 12 months, 5 in FFMI, 1 in 
LABA or LAMA, alone, 1 in inhaled corticosteroid with LABA and/or LAMA, 1 in HAD anxiety and depression, 1 in any 
COPD exacerbation with hospital admission during follow-up.  
bp-value from mixed logistic regression models with random effects for study (UT and PROactive) and city area 
(Badalona, Barcelona-center, Barcelona-shore, Mataró, Viladecans/Gavà, Athens, Edinburgh, Groningen, Leuven, 
London).  
cmarital status: living with a partner vs single, widowed or divorced.  
dworking status: active worker (working full-time or part-time) vs. unemployed, housework or retired. 
eonly available for Urban Training.  
fonly available for PROactive. 
gaverage rainfall was calculated as the mean of the measurements at baseline, 6 and 12 months.  
hThe urban vulnerability index is a measure of socioeconomic status at the census tract level that combines demographic, 
economic, residential and subjective indicators, and ranges from lowest [0] to highest [1] level of neighborhood 
vulnerability. 
ionly C-PPAC difficulty is provided as C-PPAC amount and total score include steps/day which were used for the 
generation of the PA patterns and therefore cannot be assessed as predictors.  
jICD10 codes: I00 to I99 for cardiovascular diseases; I20 to I25 for ischemic heart disease, E14 for diabetes mellitus. 
kincident comorbidities included ICD10 codes C00 to N99. 
Abbreviations: FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; 6MWD: 6-min walking distance; 
CAT: COPD Assessment Test; CCQ: Clinical COPD Questionnaire; C-PPAC: Clinical visit—PROactive Physical Activity 
in COPD (higher numbers indicate a better score); mMRC: modified Medical Research Council; BMI: body mass index; 
FFMI: fat free mass index; LABA: long-acting beta2-agonists; LAMA: long-acting anti-muscarinics; HAD-A: Hospital 




































































Table 3 Adjusted predictive factors for Inactive and Active Improvers vs Active Decliners 
in 291 COPD patients. 
 
 Active Decliners Inactive Active Improvers 
 RRR (95% CI) RRR (95% CI) p-valuea RRR (95% CI) p-valuea 















Notes: ap-value from multinomial regression model with random effects for study (UT and PROactive) and city area 
(Badalona, Barcelona-center, Barcelona-shore, Mataró, Viladecans/Gavà, Athens, Edinburgh, Groningen, Leuven, 
London). 
Abbreviations: RRR: relative risk ratio; CI: confidence interval. 6MWD: 6-min walking distance; mMRC: modified Medical 




































































Figure 1 Physical activity variables at baseline and at 12-month follow-up, overall and by 
PA progression pattern (Inactive, Active Improvers and Active Decliners).  
 
Notes: Data are presented as mean±SE (specific numbers are presented in Table S2). * p-value ≤0.05.  






Figure 2 Physical activity experience variables at baseline and at 12-month follow-up, 
overall and by PA progression pattern (Inactive, Active Improvers and Active Decliners).  
 
Notes: Data are presented as mean±SE (specific numbers are presented in Table S2). * p-value ≤0.05.  
Abbreviations: C-PPAC: Clinical visit—PROactive Physical Activity in COPD (higher numbers indicate a better score).  
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